美国结节病专科诊疗现状全景:多器官、慢性化与心脏受累突出
这项多中心纵向队列纳入美国39个州的2034例成人结节病患者,基线记录人口学、临床、肺功能及影像特征,中位随访21个月。结果显示51.8%为多器官病(即使排除淋巴结受累),66.5%病程≥3年,肺受累者中35.9%有肺纤维化且肺功能更差,基线16.2%有心脏结节病,随访新发器官事件率5.5/100患者年。
要点
- 结节病常为慢性多器官病,专科患者中需长期多学科管理。
- 肺纤维化与更差肺功能相关,合并支气管扩张时更明显。
- 心脏结节病基线占16.2%,随访中最常见的新发器官表型。
核心结论
- 结节病常呈慢性且动态演变,需针对肺纤维化和心脏结节病防治及长期多学科管理设计项目。
研究设计与样本
- 多中心纵向队列研究,纳入美国39个州的2034例成人结节病患者,中位随访21个月(IQR 9-27个月)。
主要发现
- 即使排除淋巴结受累,51.8%患者有多器官病,66.5%病程≥3年。
- 肺受累者中35.9%存在肺纤维化,与更差肺功能相关,合并支气管扩张时效应最明显。
- 基线53.4%需治疗,其中24.8%单用类固醇方案、39.7%单用非类固醇方案、35.5%联合方案。
- 随访新发器官事件120例,新发器官率5.5/100患者年(95%CI 4.6-6.6)。
- 基线心脏结节病占16.2%,新发心脏受累为随访中最常见的新器官表型。
关键数值与推荐
- 多器官病(排除淋巴结)占51.8%;慢性病程≥3年占66.5%。
- 肺纤维化占肺受累者的35.9%。
- 基线需治疗者占53.4%;单用类固醇24.8%、单用非类固醇39.7%、联合35.5%。
- 新发器官率5.5/100患者年(95%CI 4.6-6.6);基线心脏结节病16.2%。
临床怎么用
- 专科评估应系统筛查多器官受累,尤其心脏结节病。
- 对肺受累者关注肺纤维化及支气管扩张,评估肺功能恶化风险。
- 治疗决策需兼顾类固醇与非类固醇方案及联合方案,并规划长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The landscape of sarcoidosis in the United States is unclear, which makes it difficult to optimize the allocation of health care resources, clinical care programs, and research activities for sites that specialize in sarcoidosis. RESEARCH QUESTION: Can the features of sarcoidosis be defined in patients requiring specialty care in the United States to inform the design of clinical management and research programs? STUDY DESIGN AND METHODS: Adult patients with sarcoidosis were enrolled in this multicenter, longitudinal cohort study. Demographic and clinical characteristics, including lung function and imaging features, were recorded at baseline. Patients were followed up for a median of 21 months (interquartile range, 9-27 months). RESULTS: The cohort comprised 2,034 patients from 39 states. Even when excluding lymph node involvement, 51.8% of patients had multi-organ disease, and sarcoidosis was chronic (≥ 3 years) for 66.5% of patients. Pulmonary fibrosis was present in 35.9% of those with lung involvement and was associated with worse lung function, an effect most pronounced when bronchiectasis was present. Slightly more than one-half (53.4%) of the cohort required treatment at the time of study entry; of those, 24.8% were on a steroidal regimen alone, 39.7% were on a nonsteroidal regimen alone, and 35.5% were on a combination regimen. During follow-up, there were 120 new organ events, resulting in a new organ rate of 5.5 per 100 patient-years (95% CI, 4.6-6.6). Cardiac sarcoidosis was present in 16.2% of patients at baseline, and emergent cardiac involvement was the most common new organ phenotype during follow-up. INTERPRETATION: Sarcoidosis is frequently chronic and dynamic. These data support the need for programs aimed at preventing and treating pulmonary fibrosis and cardiac sarcoidosis, as well as the development of long-term, multidisciplinary management strategies.
引用
- Hena KM, Barkes B, Heinrich F, et al. An Inventory of Clinical Sarcoidosis Status in the United States. Chest. 2025. PMID: 40885536. doi:10.1016/j.chest.2025.07.4091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。